Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Non-Small Cell Lung Carcinoma
Explore 1,128 assets in Non-Small Cell Lung Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06449313CT.gov Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement | — | Recruiting | — | — | — |
NCT07450183CT.gov Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 | — | Not Yet Recruiting | — | — | — |
NCT06943664CT.gov Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07020065CT.gov Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | — | Recruiting | — | — | — |
NCT07360743CT.gov Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels | — | Not Yet Recruiting | — | — | — |
NCT06931717CT.gov A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy | — | Recruiting | — | — | — |
NCT07274384CT.gov Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial | — | Not Yet Recruiting | — | — | — |
NCT06908304CT.gov A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | — | Recruiting | — | — | — |
NCT07001618CT.gov Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06656598CT.gov Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer | — | Recruiting | — | — | — |
Show 45 more trialsShow fewer
NCT06865339CT.gov Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06917573CT.gov PALACE: Cemiplimab Trial According to ctDNA Levels | — | Recruiting | — | — | — |
NCT06616584CT.gov Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | — | Recruiting | — | — | — |
NCT06918132CT.gov Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07264673CT.gov A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study. | — | Recruiting | — | — | — |
NCT05840770CT.gov Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT06731270CT.gov Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | — | Recruiting | — | — | — |
NCT06385262CT.gov TOP 2301: Neoadjuvant Chemo for NSCLC | — | Suspended | — | — | — |
NCT06623656CT.gov Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | — | Recruiting | — | — | — |
NCT06743581CT.gov Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06219317CT.gov Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC | — | Recruiting | — | — | — |
NCT06465329CT.gov A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06463665CT.gov Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | — | Recruiting | — | — | — |
NCT06162572CT.gov Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT06532149CT.gov ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | — | Recruiting | — | — | — |
NCT06161441CT.gov A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | — | Active Not Recruiting | — | — | — |
NCT06088771CT.gov Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | — | Recruiting | — | — | — |
NCT06269133CT.gov Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients | — | Active Not Recruiting | — | — | — |
NCT06171750CT.gov Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06090266CT.gov A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | — | Recruiting | — | — | — |
NCT06052852CT.gov Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT05882734CT.gov Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | — | Active Not Recruiting | — | — | — |
NCT05800015CT.gov A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05785767CT.gov A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT05864144CT.gov A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05553834CT.gov PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung | — | Active Not Recruiting | — | — | — |
NCT05501665CT.gov Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | — | Recruiting | — | — | — |
NCT05557591CT.gov A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | — | Active Not Recruiting | — | — | — |
NCT05401786CT.gov Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT05363319CT.gov An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe | — | Recruiting | — | — | — |
NCT05317858CT.gov Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | — | Recruiting | — | — | — |
NCT05142189CT.gov Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05208944CT.gov THIO Sequenced With Cemiplimab in Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT05259696CT.gov Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) | — | Completed | — | — | — |
NCT04916002CT.gov A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | — | Terminated | — | — | — |
NCT04982224CT.gov Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer | — | Terminated | — | — | — |
NCT05094804CT.gov A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | — | Unknown | — | — | — |
NCT03916627CT.gov Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | — | Active Not Recruiting | — | — | — |
NCT03515629CT.gov REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | — | Terminated | — | — | — |
NCT03580694CT.gov Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03430063CT.gov A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | — | Terminated | — | — | — |
NCT03409614CT.gov Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | — | Completed | — | — | — |
NCT03367819CT.gov Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT03088540CT.gov Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT06132191CT.gov Expanded Access Use of Cemiplimab in Patients With Solid Tumors | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer (this asset) | University of Chicago | P3 | B · 62 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Skin Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Lung Cancer | — | P2/3 | BB · 65 |
| Nonpapillary Renal Cell Carcinoma | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-programmed-cell-death-protein-1-human-monoclonal-regn2810-heavy-chain-disulfide-with-human-monoclonal-regn2810-kappa-chain-dimer-non-small-cell-lung-carcinoma-78919
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →